Core Viewpoint - The article discusses the IPO of Changfeng Pharmaceutical, highlighting its focus on inhalation technology and its product portfolio aimed at treating respiratory diseases. The company has received multiple product approvals from regulatory authorities, indicating a strong market position and growth potential [3][10]. Company Overview - Changfeng Pharmaceutical was established in 2013 and specializes in the research, development, production, and commercialization of inhalation drugs, particularly for respiratory diseases [3]. - The company's core product is an inhalation suspension of Budesonide for treating bronchial asthma, which accounts for over 90% of its revenue [6]. Financial Performance - Revenue projections for the company are as follows: CNY 349 million in 2022, CNY 556 million in 2023, and CNY 608 million in 2024, reflecting a compound annual growth rate (CAGR) of 31.9% [6]. - The company turned a profit in 2023 with a net profit of CNY 31.73 million, but is expected to see a decline in net profit to CNY 21.09 million in 2024, a year-on-year decrease of 33.5% due to increased sales expenses [6][7]. IPO Details - The IPO subscription period for Changfeng Pharmaceutical is from September 26 to October 2, with a global offering of 41.198 million shares at a price of HKD 14.75 per share [10]. - The offering includes 4.12 million shares available in Hong Kong, with a high demand indicated by nearly 500 times subscription, suggesting strong investor interest [10].
【港股IPO】长风药业，专注治疗呼吸系统疾病，入场费7449港元